ecDTx Pipeline (Lead Candidate)

About Boundless Bio

Boundless Bio is a clinical-stage biotechnology company focused on developing transformative medicines for patients with oncogene-amplified cancers, a population with poor prognosis and limited treatment options. The company leverages its foundational discoveries in extrachromosomal DNA (ecDNA) biology to create a new vertical of cancer therapeutics, ecDNA-directed therapies (ecDTx), which aim to exploit unique vulnerabilities in cancer cells. With a leadership team of experienced precision oncology experts and a robust pipeline, Boundless Bio is positioned as the leader in the emerging field of ecDNA-targeted oncology. The company is unbound by convention in its mission to address a significant unmet medical need in oncology.

Therapeutic Areas

Other Oncogene-amplified solid tumors Drugs